CCL2 and rheumatoid arthritis: From our results, after anti-CCL2 antibody treatment, control MSCs also lost their capacity to modulate Th17 cells in vitro (Figure 1), suggesting lack of CCL2 production may weaken the regulation capacity of RA MSCs on Th17 cells.